{
    "2021-10-28": [
        [
            {
                "time": "",
                "original_text": "【专题报告】2021年三季报公募基金十大重仓股持仓分析",
                "features": {
                    "keywords": [
                        "2021年三季报",
                        "公募基金",
                        "重仓股",
                        "持仓分析"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "金融",
                        "基金"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "逆势上扬的CRO：一半是海水，一半是火焰",
                "features": {
                    "keywords": [
                        "CRO",
                        "逆势上扬",
                        "海水",
                        "火焰"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "华鑫证券维持凯莱英推荐评级：各项指标优秀，业绩符合预期",
                "features": {
                    "keywords": [
                        "华鑫证券",
                        "凯莱英",
                        "推荐评级",
                        "业绩符合预期"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "东吴证券维持凯莱英买入评级：业绩符合预期，公司未来发展有望不断提速",
                "features": {
                    "keywords": [
                        "东吴证券",
                        "凯莱英",
                        "买入评级",
                        "业绩符合预期",
                        "未来发展提速"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "【医药生物】凯莱英—业绩稳定增长，持续建设产能服务能力",
                "features": {
                    "keywords": [
                        "医药生物",
                        "凯莱英",
                        "业绩稳定增长",
                        "产能建设"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "港股盘前必读：中国平安前三季度净利润816.38亿元同比下降20.8%",
                "features": {
                    "keywords": [
                        "港股",
                        "中国平安",
                        "净利润",
                        "同比下降"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "保险",
                        "金融"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "高瓴患上“减持尴尬症” | 巨潮 减持股份",
                "features": {
                    "keywords": [
                        "高瓴",
                        "减持",
                        "尴尬症",
                        "巨潮"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "投资",
                        "资本"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}